[
  {
    "ts": "2026-01-31T17:35:54+00:00",
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most profitable healthcare stocks to buy. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported Q4 2025 results on January 30, with revenue coming in at $3.9 billion (+3.0% year over year), which were around 3% ahead of consensus. Profitability was even better with adjusted EPS for the quarter reaching $11.44, 7% […]",
    "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-posts-173554503.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "de7a7694-6f94-3fb4-99db-7dc3880278c3",
      "content": {
        "id": "de7a7694-6f94-3fb4-99db-7dc3880278c3",
        "contentType": "STORY",
        "title": "Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines",
        "description": "",
        "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most profitable healthcare stocks to buy. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported Q4 2025 results on January 30, with revenue coming in at $3.9 billion (+3.0% year over year), which were around 3% ahead of consensus. Profitability was even better with adjusted EPS for the quarter reaching $11.44, 7% […]",
        "pubDate": "2026-01-31T17:35:54Z",
        "displayTime": "2026-01-31T17:35:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/a7afd85ac72398ddfb23a21efa2d2f7d",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GNORuynkkfSFB6cihL2fBw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/a7afd85ac72398ddfb23a21efa2d2f7d.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KZlZnexVQ9t4nV6UduMakg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a7afd85ac72398ddfb23a21efa2d2f7d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-posts-173554503.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-posts-173554503.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]